A recent head-to-head study of Gla-300 vs IDeg-100 in insulin-naive individuals with type 2 diabetes demonstrated that both second-generation longer-acting basal insulin analogues were associated with comparable reductions in HbA1c, glucose profiles, and fasting SMPG.

Second-generation insulin analogues have provided physicians with agents that can provide comparable glycaemic control to first-generation insulin, but with a reduced risk of hypoglycaemia and modes of action suited to once-daily regimens.

Please sign in to read more